{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:40:29Z","timestamp":1791999629046,"version":"4.4.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Vitiligo is an autoimmune disease characterized by the loss of skin pigmentation due to the loss of melanocytes. The pathogenesis of vitiligo is complex, involving multiple genetic factors, environmental triggers, oxidative stress, and autoimmunity against melanocytes. Stressed melanocytes release damage-associated molecular patterns, which trigger increased activation of antigen presenting cells, leading to maturation and activation of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells that respond to auto-melanocyte-specific antigens. Once recruited to melanocytes, cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cells produce cytokines, including primarily the type 1 cytokine IFN-\u03b3, but also IL-2, IL-15, and type 2-related cytokines. Cytokines bind to fibroblasts, melanocytes, and keratinocytes to induce a positive feedback loop of immune cell recruitment to lesions, immune cell activation, and melanocyte apoptosis. The JAK\/STAT pathway and TEC family kinase signaling play key roles in vitiligo pathogenesis through chemokine production, reduction of melanocyte adhesion, and immune cell activation and disease maintenance. This review summarizes recent key advances in understanding how these pathways impact vitiligo pathogenesis and details the emergence of new targeted therapies for the treatment of vitiligo.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1662245","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:37:50Z","timestamp":1773643070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of JAK3 and TEC family kinases in vitiligo pathogenesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[{"name":"University C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire Nice, Department of Dermatology","place":["Nice, France"]},{"name":"University C\u00f4te d\u2019Azur, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM), U1065, C3M","place":["Nice, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164","place":["Bordeaux, France"]},{"name":"University Bordeaux, French National Center for Scientific Research (CNRS), Immuno ConcEpT, UMR 5164","place":["Bordeaux, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Picardo","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico Immacolata, Scientific Hospitalization and Treatment Institute (IRCCS)","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihong","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanemura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Integrated Medicine, Osaka University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Winkler","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Telliez","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Adiri","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceutical Israel LTD","place":["Herzliya Pituach, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: A review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.002","article-title":"Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients","volume":"35","author":"Elbuluk","year":"2017","journal-title":"Dermatol Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0172-x","article-title":"Social anxiety and quality of life in vitiligo and acne patients with facial involvement: A cross-sectional controlled study","volume":"17","author":"Salman","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: A systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15199","article-title":"Vitiligo and depression: a systematic review and meta-analysis of observational studies","volume":"177","author":"Lai","year":"2017","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: A systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6663646","article-title":"Meta-analytic review of high anxiety comorbidity among patients with vitiligo","volume":"2021","author":"Liu","year":"2021","journal-title":"BioMed Res Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14739","article-title":"The prevalence and odds of depression in patients with vitiligo: a meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e69697","DOI":"10.7759\/cureus.69697","article-title":"Updates on the association between vitiligo and thyroid diseases: A systematic review","volume":"16","author":"Abuhalimeh","year":"2024","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.142493","article-title":"Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study","volume":"5","author":"Gopal","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.11.772","article-title":"Skin manifestations of diabetes","volume":"75","author":"Van Hattem","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2016.00003","article-title":"Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci","volume":"7","author":"Shen","year":"2016","journal-title":"Front Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084409","article-title":"Pathogenesis of alopecia areata and vitiligo: commonalities and differences","volume":"25","author":"Yamaguchi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12863-024-01254-6","article-title":"Estimation of genetic variation in vitiligo associated genes: Population genomics perspective","volume":"25","author":"Bharti","year":"2024","journal-title":"BMC Genom Data"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.542275","article-title":"Validation of susceptibility loci for vitiligo identified by GWAS in the chinese han population","volume":"11","author":"Cheng","year":"2020","journal-title":"Front Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/jid.2009.347","article-title":"Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8","volume":"130","author":"Birlea","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1002\/ctm2.1810","article-title":"Vitiligo auto-immune response upon oxidative stress-related mitochondrial DNA release opens up new therapeutic strategies","volume":"14","author":"Sant\u2019Anna-Silva","year":"2024","journal-title":"Clin Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-78655-1","volume-title":"Damage-associated molecular patterns in human diseases","author":"Land","year":"2018"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.036","article-title":"Analysis of matched skin and gut microbiome of patients with vitiligo reveals deep skin dysbiosis: link with mitochondrial and immune changes","volume":"141","author":"Bzioueche","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133772","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.007","article-title":"Emerging role of fibroblasts in vitiligo: A formerly underestimated rising star","volume":"144","author":"Wu","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through jak signaling","volume":"142","author":"Martins","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1016\/j.jid.2024.03.036","article-title":"IL-12\/IL-23-independent function of BATF3-dependent dendritic cells is required for initiation of disease in a mouse model of vitiligo","volume":"144","author":"Frisoli","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2250281","DOI":"10.1002\/eji.202250281","article-title":"The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","journal-title":"Eur J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eabd8995","DOI":"10.1126\/scitranslmed.abd8995","article-title":"scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T","volume":"13","author":"Gellatly","year":"2021","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression","volume":"137","author":"Rezk","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.1365-2133.2003.05024.x","article-title":"Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo","volume":"148","author":"Gauthier","year":"2003","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469795","article-title":"In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects","volume":"88","author":"Puri","year":"1987","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.65","article-title":"Melanocytes as instigators and victims of oxidative stress","volume":"134","author":"Denat","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00087.x","article-title":"Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients","volume":"16","author":"Dell\u2019Anna","year":"2003","journal-title":"Pigment Cell Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03876.x","article-title":"Depigmentation therapies for normal skin in vitiligo universalis","volume":"25","author":"AlGhamdi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.017","article-title":"Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: Appearances can be deceptive","volume":"153","author":"Migayron","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e14649","DOI":"10.1111\/dth.14649","article-title":"Evaluation of the effect of narrow band-ultraviolet B on the expression of tyrosinase, TYRP-1, and TYRP-2 mRNA in vitiligo skin and their correlations with clinical improvement: A retrospective study","volume":"34","author":"Awad","year":"2021","journal-title":"Dermatol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","article-title":"Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2023.110737","article-title":"Altered regulatory T cell-mediated Natural Killer cells suppression may lead to generalized vitiligo","volume":"85","author":"Giri","year":"2024","journal-title":"Hum Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) t cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: A review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11429","DOI":"10.3390\/ijms222111429","article-title":"Role of cytokines in vitiligo: pathogenesis and possible targets for old and new treatments","volume":"22","author":"Custurone","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1159\/000510831","article-title":"Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: A case report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: an update on pathophysiology and treatment options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14001","article-title":"A review of JAK and IL-23 inhibitors to treat vitiligo","volume":"64","author":"Lee","year":"2023","journal-title":"Australas J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.08.043","article-title":"Guselkumab-induced vitiligo in a patient with psoriatic arthritis","volume":"41","author":"Martora","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12978","article-title":"Presence and the roles of IL-9\/Th9 axis in vitiligo","volume":"34","author":"Kumar","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103552","article-title":"The role of TRM cells in the pathogenesis of vitiligo-A review of the current state-of-the-art","volume":"21","author":"Fraczek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16680","article-title":"Melanocyte-specific CD49a","volume":"50","author":"Yokoi","year":"2023","journal-title":"J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transd Targ Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s1054-3589(08)60111-8","article-title":"Cytokines and STAT signaling","volume":"47","author":"Schindler","year":"2000","journal-title":"Adv Pharmacol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s0092-8674(00)81168-x","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell May 01"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.7.3327","article-title":"Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha\/beta and for signal transduction","volume":"270","author":"Velazquez","year":"1995","journal-title":"J Biol Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B76","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","volume":"153","author":"Guttman-Yassky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13879","article-title":"Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells","volume":"28","author":"Boniface","year":"2019","journal-title":"Exp Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2079","article-title":"Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells","volume":"12","author":"Feau","year":"2011","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280349","article-title":"Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer\/T-cell lymphoma","volume":"107","author":"Picod","year":"2022","journal-title":"Haematologica"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.3390\/cells10081955","article-title":"Implications of a \u2018Third signal\u2019 in NK cells","volume":"10","author":"Khalil","year":"2021","journal-title":"Cells"},{"key":"B85","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/mi.2017.38","article-title":"Jak3 deficiency blocks innate lymphoid cell development","volume":"11","author":"Robinette","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(99)00019-2","article-title":"Tec family of protein-tyrosine kinases: an overview of their structure and function","volume":"10","author":"Mano","year":"1999","journal-title":"Cytokine Growth Factor Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nri1591","article-title":"TEC-family kinases: regulators of T-helper-cell differentiation","volume":"5","author":"Schwartzberg","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/j.1742-4658.2011.08135.x","article-title":"Tec family kinases","volume":"278","author":"Yu","year":"2011","journal-title":"FEBS J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00746.x","article-title":"The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development","volume":"228","author":"Prince","year":"2009","journal-title":"Immunol Rev"},{"key":"B90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/08830185.2012.670334","article-title":"Tec family kinases in inflammation and disease","volume":"31","author":"Horwood","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102842","article-title":"Targeting ITK signaling for T cell-mediated diseases","volume":"24","author":"Weeks","year":"2021","journal-title":"iScience"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/s1074-7613(00)80115-6","article-title":"Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells","volume":"11","author":"Fowell","year":"1999","journal-title":"Immunity"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3007","article-title":"The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival","volume":"180","author":"Felices","year":"2008","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.614891","article-title":"Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694","volume":"290","author":"Zhong","year":"2015","journal-title":"J Biol Chem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01958-z","article-title":"Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis","volume":"98","author":"Lechner","year":"2020","journal-title":"J Mol Med (Berl)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1146\/annurev.immunol.22.012703.104743","article-title":"Tec family kinases in T lymphocyte development and function","volume":"23","author":"Berg","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.07.009","article-title":"Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase","volume":"31","author":"Gomez-Rodriguez","year":"2009","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.4.2.147","article-title":"Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet\u2019s disease","volume":"4","author":"Suzuki","year":"2006","journal-title":"Clin Med Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1330","article-title":"Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase","volume":"117","author":"Ferrara","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.04.011","article-title":"Requirement for Tec kinases in chemokine-induced migration and activation of Cdc42 and Rac","volume":"14","author":"Takesono","year":"2004","journal-title":"Curr Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.11.1611","article-title":"Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk","volume":"192","author":"Ellmeier","year":"2000","journal-title":"J Exp Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.6.2455-2466.2004","article-title":"Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec","volume":"24","author":"Tomlinson","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)93004-1","article-title":"Tec kinases in T cell and mast cell signaling","volume":"93","author":"Felices","year":"2007","journal-title":"Adv Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.017","article-title":"Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function","volume":"36","author":"Lin","year":"2012","journal-title":"Immunity"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41467-017-01477-5","article-title":"Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells","volume":"8","author":"Lin","year":"2017","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jcph.2347","article-title":"Target occupancy and functional inhibition of JAK3 and TEC family kinases by ritlecitinib in healthy adults: an open-label, phase 1 study","volume":"64","author":"Martin","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J Biol Chem"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4103\/2321-3868.135483","article-title":"Current understanding of tyrosine kinase BMX in inflammation and its inhibitors","volume":"2","author":"Qiu","year":"2014","journal-title":"Burns Trauma"},{"key":"B110","first-page":"1717","article-title":"Vitiligo","volume":"2008","author":"Matin","year":"2008","journal-title":"BMJ Clin Evid"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20311","article-title":"Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences","volume":"39","author":"Yamaguchi","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: A systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15858","article-title":"Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients","volume":"48","author":"Wada-Irimada","year":"2021","journal-title":"J Dermatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185785","article-title":"Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity","volume":"135","author":"Ezzedine","year":"2025","journal-title":"J Clin Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104499","article-title":"FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B122","unstructured":"VIPOC\n          Incyte announces european commission approval of opzelura\n          \n          2023"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"B126","unstructured":"Prescribing information"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B128","unstructured":"Incyte\n          Incyte presents new late-breaking data from phase 2 study evaluating povorcitinib in patients with prurigo nodularis\n          \n          2024"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.791","article-title":"53962 efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial","volume":"91","author":"Pandya","year":"2024","journal-title":"JAAD"},{"key":"B130","unstructured":"Prescribing information\n          \n          2022"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.5737","article-title":"Combination of baricitinib and phototherapy in adults with active vitiligo: A randomized clinical trial","volume":"161","author":"Seneschal","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"B133","unstructured":"an oral JAK inhibitor for the treatment of severe alopecia areata\n          \n          2024"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","volume":"315","author":"Mikhaylov","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00837-w","article-title":"Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors","volume":"25","author":"Kim","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17278","article-title":"Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial","volume":"35","author":"Wollenberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B140","article-title":"New non-steroidal topical therapies for inflammatory dermatoses-part 1: ruxolitinib","volume":"21","author":"Mancuso-Stewart","year":"2023","journal-title":"Skinmed"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B143","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15\u2013000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01555-3","article-title":"Long-term integrated safety summary of ruxolitinib cream in phase 3 clinical trials of patients with vitiligo","volume":"15","author":"Rosmarin","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"215\u201327","DOI":"10.1093\/bjd\/ljae365","article-title":"Efficacy and safety of the oral JAK3\/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b\/3 and long-term phase 3 clinical studies in alopecia areata","volume":"192","author":"Piliang","year":"2024","journal-title":"Br J Dermatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00932-0","article-title":"Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3 years and up to 4 years of treatment","volume":"26","author":"King","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00937-9","article-title":"Incidence rates of infections, Malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database","volume":"13","author":"George","year":"2023","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1662245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:37:53Z","timestamp":1773643073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1662245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":153,"alternative-id":["10.3389\/fimmu.2026.1662245"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1662245","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1662245"}}